Featured Research

from universities, journals, and other organizations

Targeting memory t-cells in type 1 diabetes

Date:
September 22, 2013
Source:
Immune Tolerance Network
Summary:
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes) are published today. The T1DAL trial was designed to test whether alefacept would preserve pancreatic beta cell function in newly diagnosed patients. Secondary endpoints including insulin use and rate of hypoglycemic events were lower at 12 months in the alefacept treated group.

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby MD, PhD from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

Related Articles


Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first biologic therapy approved for moderate to severe plaque psoriasis. By binding CD2, alefacept inhibits co-stimulation and induces T-cell depletion. T-cell mediated destruction of insulin producing pancreatic beta cells is a central feature of Type 1 diabetes, but targeting of CD2 has not previously been evaluated in this disease. The T1DAL trial was designed to test whether alefacept would preserve pancreatic beta cell function in newly diagnosed patients.

The Phase II T1DAL study enrolled 49 new-onset type 1 diabetic subjects, ages 12 to 35, who were randomized into two groups: 33 to alefacept and 16 to placebo. Patients received two twelve week courses (separated by a 12 week pause) of either alefacept or placebo. Twelve months from the start of the study, patients underwent a mixed meal tolerance test to measure the C-peptide response (a measure of insulin production). The primary endpoint, a 2-hour C-peptide response, did not show statistically significant differences between treatment and placebo groups; however, a secondary endpoint, a 4-hour C-peptide response, was significantly higher at 12 months in the treatment group compared to the placebo group. Other secondary endpoints including insulin use and rate of hypoglycemic events were significantly lower at 12 months in the alefacept treated group.

Although the primary endpoint was not met, these encouraging results of key secondary endpoints suggest a disease-modifying effect of alefacept. Additional support for alefacept's therapeutic role comes from analysis of T-cell subtypes of treated patients that showed that effector T cells were primarily targeted while sparing protective regulatory T cells. Lead investigator Dr. Mark Rigby suggests, "The T1DAL study is the first to use an agent to specifically deplete the cells which attack the pancreas in type 1 diabetes, the memory and effector T cells. We also found that regulatory T cells are not depleted with this therapy, suggesting that immune re-education can take place."

Longer 24 month follow-up of the subjects in this study is in progress to evaluate the potential for durable efficacy of the alefacept treatment. "Unfortunately our study was not able to enroll the goal number of participants due to drug availability which prevented more definitive conclusions at this point," said Dr. Rigby. "We are eagerly awaiting additional data over the next year which will help us determine if targeting memory T cells will help those with Type 1 diabetes make insulin for extended periods."


Story Source:

The above story is based on materials provided by Immune Tolerance Network. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mark R Rigby, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Chetanbabu M Patel, Kurt J Griffin, Eva Tsalikian, Peter A Gottlieb, Carla J Greenbaum, Nicole A Sherry, Wayne V Moore, Roshanak Monzavi, Steven M Willi, Philip Raskin, Antoinette Moran, William E Russell, Ashley Pinckney, Lynette Keyes-Elstein, Michael Howell, Sudeepta Aggarwal, Noha Lim, Deborah Phippard, Gerald T Nepom, James McNamara, Mario R Ehlers. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Diabetes & Endocrinology, 2013; DOI: 10.1016/S2213-8587(13)70111-6

Cite This Page:

Immune Tolerance Network. "Targeting memory t-cells in type 1 diabetes." ScienceDaily. ScienceDaily, 22 September 2013. <www.sciencedaily.com/releases/2013/09/130922205910.htm>.
Immune Tolerance Network. (2013, September 22). Targeting memory t-cells in type 1 diabetes. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/09/130922205910.htm
Immune Tolerance Network. "Targeting memory t-cells in type 1 diabetes." ScienceDaily. www.sciencedaily.com/releases/2013/09/130922205910.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins